南非COVID-19门诊患者五臂随机临床试验的社区管理:挑战与机遇
本文介绍在南非约翰内斯堡与多方合作开展的一项随机、适应性、开放标签2期临床试验的规划与管理经验,该试验评估四种老药新用方案对比标准治疗对轻至中度COVID-19门诊患者的安全性和有效性,研究于2020年9月3日至2021年8月23日进行,面临疫情限制、发病率与死亡率高峰及供应链、经济和政治不稳定等挑战。
要点
- 试验设计务实,纳入低风险患者并采用开放标签治疗,内置样本量调整和多项次要疗效终点。
- 招募障碍包括疫情波次时机、人员因病短缺、患者就诊延迟、COVID-19错误信息和政治动荡。
- 缓解措施包括使用社区卫生工作者、部署移动临床单元和简化筛查,远程培训与监测、电子知情同意、患者居家采样和报告数据及远程医疗等措施成功用于数据收集且安全、受患者欢迎。
核心结论
- 在大流行高峰期完成COVID-19门诊试验需要在临床试验管理几乎每个方面进行多项创新,需要研究工作人员和患者的高度承诺以及研究申办方的支持。
- 我们的经验建立了更稳健的临床研究基础设施,将效率构建到临床试验管理中,超越大流行之外。
研究设计与样本
- 随机、适应性、开放标签2期临床试验,评估四种老药新用方案对比标准治疗对轻至中度COVID-19门诊患者的安全性和有效性。
- 研究地点为南非约翰内斯堡,与多方利益相关者合作,研究于2020年9月3日至2021年8月23日进行。
- 试验设计务实,纳入低风险患者,采用开放标签治疗,内置样本量调整和多项次要疗效终点。
主要发现
- 招募障碍包括疫情波次时机、人员因病短缺、患者就诊延迟、COVID-19错误信息和政治动荡。
- 缓解措施包括使用社区卫生工作者、部署移动临床单元和简化筛查。
- 试验管理措施包括远程工作人员培训与监测、电子知情同意、患者培训和支持居家采样与报告数据、引入远程医疗。
- 上述措施对数据收集成功、安全且受患者欢迎。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Repeated COVID-19 waves and corresponding mitigation measures have impacted health systems globally with exceptional challenges. In response to the pandemic, researchers, regulators, and funders rapidly pivoted to COVID-19 research activities. However, many clinical drug studies were not completed, due to often complex and rapidly evolving research conditions. METHODS: We outline our experience of planning and managing a randomised, adaptive, open-label, phase 2 clinical trial to evaluate the safety and efficacy of four repurposed drug regimens versus standard-of-care (SOC) in outpatients with 'mild to moderate' COVID-19 in Johannesburg, South Africa, in the context of a partnership with multiple stakeholders. The study was conducted between 3 September 2020 and 23 August 2021 during changing COVID-19 restrictions, significant morbidity and mortality waves, and allied supply line, economic, and political instability. RESULTS: Our clinical study design was pragmatic, including low-risk patients who were treated open label. There was built-in flexibility, including provision for some sample size adjustment and a range of secondary efficacy outcomes. Barriers to recruitment included the timing of waves, staff shortages due to illness, late presentation of patients, COVID-19 misinformation, and political unrest. Mitigations were the use of community health workers, deployment of mobile clinical units, and simplification of screening. Trial management required a radical reorganisation of logistics and processes to accommodate COVID-19 restrictions. These included the delivery of staff training and monitoring remotely, electronic consent, patient training and support to collect samples and report data at home, and the introduction of tele-medicine. These measures were successful for data collection, safe, and well received by patients. CONCLUSION: Completing a COVID-19 trial in outpatients during the height of the pandemic required multiple innovations in nearly every aspect of clinical trial management, a high commitment level from study staff and patients, and support from study sponsors. Our experience has generated a more robust clinical research infrastructure, building in efficiencies to clinical trial management beyond the pandemic.
引用
- Chandiwana N, Kruger C, Richardson N, et al. Community-based management of a five-arm randomised clinical trial in COVID-19 outpatients in South Africa: challenges and opportunities. Trials. 2023. PMID: 37794489. doi:10.1186/s13063-023-07577-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。